Celgene Revamps IO Deal With Emerging Biotech Sutro; Takeover Option Removed

Celgene and small Californian biotech Sutro have renovated their 2014 cancer drug discovery deal to grant Celgene worldwide rights to the first two products to emerge from the arrangement, and to lift restrictions on Sutro accessing public financial markets.

Businessman comparing two documents, neutral background
Celgene and Sutro redraft 2014 immuno-oncology deal • Source: Shutterstock

The restructuring of a 2014 discovery and development deal for immuno-oncology assets means Celgene Corp. no longer has the option of acquiring its small biotech partner, Sutro Biopharma Inc.

In what the two firms have called a "refocus," restrictions have also been lifted that previously prevented Sutro agreeing additional...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.